ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1680

Major salivary gland ultrasonographic features of lymphoma and high lymphoproliferative risk lesions in Sjögren’s Disease: a systematic review

Alen Zabotti1, Valeria Manfrè1, Maria Teresa Rizzo1, Alessia Nano1, Garifallia Sakellariou2 and Luca Quartuccio1, 1Division of Rheumatology, Department of Medicine (DMED), Academic Hospital "Santa Maria della Misericordia", ASUFC, University of Udine, Udine, Italy, Udine, Italy, 2Department of Internal Medicine and Therapeutics, Università Di Pavia, Pavia, Italy; Istituti Clinici Scientifici Maugeri IRCCS Pavia, Pavia, Italy

Meeting: ACR Convergence 2025

Keywords: Biomarkers, Imaging, Sjögren's syndrome, Ultrasound

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: Abstracts: Sjögren’s Disease – Basic & Clinical Science (1680–1685)

Session Type: Abstract Session

Session Time: 1:00PM-1:15PM

Background/Purpose: Sjögren’s disease (SjD) is burdened by significant lymphoproliferative risk. Up to date there is no established consensus on the salivary gland ultrasonographic (SGUS) features of lymphoma or of high lymphoproliferative risk (HLR) lesions (e.g., LELs, GCs, MESA/LESA). The aim is to systematically review existing literature on SGUS features of SjD patients complicated by SG Lymphoma or HLR lesions.

Methods: A systematic review of existing literature (SLR) (January 1988 – January 2025) was conducted according to PRISMA 2020 guidelines (Prospero registration: CRD420251008467).

Results: 15 studies (13 full text articles, 2 international conference abstracts) were included, with a predominantly moderate-low risk of bias (Figure 1). 13/15 described SGUS features of lymphoma, considering 121 total cases. 11/13 described the presence of focal lesions in lymphomas (8/11 quantitatively), identifying 45 focal lesions on 117 cases. These lesions were described with variable features, but commonly presented as a dominant glandular hypo- to anechoic mass on SGUS (Table 1). In 3/11 studies, the parenchyma surrounding the focal lesion was also assessed, with quantitative or inferable SGUS scores indicating moderate to severe involvement in all cases (Table 1). 10/13 studies described a diffuse glandular involvement (presence of SGUS abnormalities) in lymphoma cases (7/10 quantitatively), identifying 32 cases on 105 lymphomas. 4/10 studies quantitatively reported SGUS scores, with moderate-severe involvement in most cases (Table 2). 9/15 studies described HLR lesions, with a total of 161 quantifiable cases. In 4/9 a focal lesion in HLR cases was described, resulting in 11 focal lesions on 16 HLR cases considered, with descriptions and features as heterogeneous as lymphomas. Only 1/4 studies addressed SGUS features of the surrounding parenchyma, reporting a severe grade (Tab.2). 5/9 studies reported a diffuse involvement in the absence of mention of focal lesions in HLR lesions (only 3 quantitatively), identifying 77 cases on 149 HLR lesions. 2/5 of these studies address SGUS scores reporting quantitative measures, more frequently a moderate-severe involvement (Table 2). No prospective studies define SGUS’s role in detecting or predicting lymphoproliferative evolution.

Conclusion: The SLR confirms that both major salivary gland lymphoma and HLR lesions in SjD can appear as a dominant focal lesion (mostly hypo-anechoic lesion/mass), or as a diffuse involvement (mostly moderate-severe SGUS scores). SGUS features are described with highly heterogenous methodology and terminology, thus highlighting the necessity of a standardization in the reporting measures.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: A. Zabotti: AbbVie/Abbott, 2, 5, Amgen, 2, 5, Eli Lilly, 2, 5, Johnson & Johnson, 2, 5, 6, Novartis, 2, 5, UCB, 2, 5; V. Manfrè: None; M. Rizzo: None; A. Nano: None; G. Sakellariou: None; L. Quartuccio: None.

To cite this abstract in AMA style:

Zabotti A, Manfrè V, Rizzo M, Nano A, Sakellariou G, Quartuccio L. Major salivary gland ultrasonographic features of lymphoma and high lymphoproliferative risk lesions in Sjögren’s Disease: a systematic review [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/major-salivary-gland-ultrasonographic-features-of-lymphoma-and-high-lymphoproliferative-risk-lesions-in-sjogrens-disease-a-systematic-review/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/major-salivary-gland-ultrasonographic-features-of-lymphoma-and-high-lymphoproliferative-risk-lesions-in-sjogrens-disease-a-systematic-review/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology